Oak Thistle LLC’s Quest Diagnostics DGX Stock Holding History

Oak Thistle LLC’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,132	Closed	-$1.24M	–	511
2025 Q4	$1.24M	Buy	7,132 +3,299	+86%	+$601K	0.17%	250
2025 Q3	$730K	Buy	3,833 +2,088	+120%	+$371K	0.11%	322
2025 Q2	$313K	Sell	1,745 -3,474	-67%	-$603K	0.05%	408
2025 Q1	$883K	Sell	5,219 -2,713	-34%	-$446K	0.18%	216
2024 Q4	$1.2M	Buy	7,932 +5,653	+248%	+$879K	0.36%	95
2024 Q3	$354K	Sell	2,279 -358	-14%	-$53.5K	0.12%	305
2024 Q2	$361K	Buy	+2,637	New	+$361K	0.27%	166
2024 Q1	–	Sell	-6,261	Closed	-$863K	–	346
2023 Q4	$863K	Buy	6,261 +1,480	+31%	+$195K	0.25%	163
2023 Q3	$583K	Buy	4,781 +826	+21%	+$110K	0.17%	250
2023 Q2	$556K	Buy	+3,955	New	+$545K	0.29%	139
2022 Q2	–	Sell	-1,543	Closed	-$211K	–	240
2022 Q1	$211K	Buy	+1,543	New	+$215K	0.11%	341

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Oak Thistle LLC's DGX Position: Q1 2026 in Review

Oak Thistle LLC sold out of Quest Diagnostics (DGX) in Q1 2026, closing a stake of 7,132 shares — an estimated $1.24M sold.

Oak Thistle LLC first reported a position in DGX in Q1 2022 and held it in 11 quarters. The position peaked at $1.24M in Q4 2025. 1,069 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

Oak Thistle LLC reported no remaining Quest Diagnostics position as of Q1 2026 after selling out during the quarter.
Oak Thistle LLC sold 7,132 Quest Diagnostics shares in Q1 2026, an estimated $1.24M.
Oak Thistle LLC first reported a position in Quest Diagnostics in Q1 2022 and held it in 11 quarters.
Oak Thistle LLC's Quest Diagnostics position peaked at $1.24M in Q4 2025.
1,069 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Oak Thistle LLC's 13F filing for Q1 2026, filed 13 Apr 2026.